Apple Tree Partners cultivated its latest startup, Elstar Therapeutics Inc. – named for a European variety of the fruit – packed the C-suite with big pharma veterans and pollinated the newco with a $39 million series A. The round was sized to begin building a pipeline of candidates from Elstar's universal targeted immunotherapy, or Uniti, platform to address both hematologic and solid tumor indications.